Sucampo Pharmaceuticals SCMP (SPI) today announced that RESCULA (unoprostone
isopropyl ophthalmic solution) 0.15% is now available by prescription
across the United States. The U.S. Food and Drug Administration (FDA)
approved a sNDA for RESCULA for the lowering of intraocular pressure
(IOP) in patients with open-angle glaucoma or ocular hypertension on
December 7, 2012.
“RESCULA is an important prostone-based treatment option for patients
suffering from open-angle glaucoma, which is the most common form of
glaucoma,” said Sucampo's Chairman, Chief Executive Officer, and Chief
Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D. “We have already
received positive feedback from many in the ophthalmology and optometry
communities regarding RESCULA's unique mechanism of action
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in